Introduction Obesity is frequently a comorbidity of type 2 diabetes. Even modest weight loss
can significantly improve glucose homeostasis and lessen cardiometabolic risk factors in …

During the last decade we experienced a surge in the number of glucose lowering agents
that can be used to treat patients with type 2 diabetes. Especially important are the …

Objective This consensus statement provides (1) visual guidance in concise graphic
algorithms to assist with clinical decision-making of health care professionals in the …

Background and aims Sodium-glucose co-transporter-2 inhibitors (SGLT2i) may have
important benefits for the elderly with type 2 diabetes (T2D), however some safety concerns …

Elevated blood pressure and hyperglycaemia frequently coexist and are both components of
metabolic syndrome. Enhanced cardiovascular risk is strongly associated with diabetes and …

Aims SURE Italy, a multicentre, prospective, open‐label, observational, real‐world study,
investigated once‐weekly semaglutide in patients with type 2 diabetes (T2D) in routine …

Type 2 diabetes mellitus (T2DM) is highly prevalent and associated with a two-fold
increased mortality, mostly explained by cardiovascular diseases. Trial evidence on older …

Chronic kidney disease (CKD) is an independent risk factor for stroke and covert
cerebrovascular disease, and up to 40% of stroke patients have concomitant CKD. However …

Introduction Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic
cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a …

Dapagliflozin has been demonstrated to improve glycemic control, blood pressure, and body
weight in type 2 diabetes mellitus (T2D); indeed, it can also reduce the risk of progression to …